$1.70
0.59% yesterday
Nasdaq, Nov 25, 09:30 pm CET
ISIN
US87424L1089
Symbol
TLIS

Talis Biomedical Corp Stock price

$1.69
+0.00 0.00% 1M
-7.31 81.22% 6M
-5.76 77.32% YTD
-5.68 77.07% 1Y
-69.56 97.63% 3Y
-238.31 99.30% 5Y
-238.31 99.30% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US87424L1089
Symbol
TLIS
Sector

Key metrics

Market capitalization $53.55m
Enterprise Value $12.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 41.60
P/S ratio (TTM) P/S ratio 178.50
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth -70.65%
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-49.26m
Free Cash Flow (TTM) Free Cash Flow $-40.24m
Cash position $59.87m
EPS (TTM) EPS $-28.02
Short interest 1.54%
Show more

Is Talis Biomedical Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Talis Biomedical Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Talis Biomedical Corp:

1x Sell
100%

Analyst Opinions

1 Analyst has issued a forecast Talis Biomedical Corp:

Sell
100%

Financial data from Talis Biomedical Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.30 0.30
71% 71%
100%
- Direct Costs 1.24 1.24
93% 93%
413%
-0.94 -0.94
94% 94%
-313%
- Selling and Administrative Expenses 27 27
875% 875%
8,877%
- Research and Development Expense 20 20
64% 64%
6,827%
-48 -48
36% 36%
-16,013%
- Depreciation and Amortization 1.22 1.22
91% 91%
407%
EBIT (Operating Income) EBIT -49 -49
44% 44%
-16,420%
Net Profit -51 -51
41% 41%
-17,010%

In millions USD.

Don't miss a Thing! We will send you all news about Talis Biomedical Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Talis Biomedical Corp Stock News

Negative
InvestorPlace
4 months ago
Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.

Company Profile

Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Menlo Park, CA.

Head office United States
CEO Robert Kelley
Employees 99
Founded 2013
Website talisbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today